Peripheral Arterial Disease Trial, Recruiting NCT07157475 Sponsor: Wroclaw Medical University Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT07157475
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have had, or are scheduled to have, a blood vessel procedure on your legs (either open surgery or a less invasive procedure) because of poor blood flow, either sudden or long-term
  • You have been taking a type of medication called an SGLT2 inhibitor (also known as "flozins," such as empagliflozin, dapagliflozin, or canagliflozin) for at least 3 months before the procedure, or you start taking one right after the procedure — this applies only to one group in the trial; the reason you were prescribed this medication (kidney disease, heart problems, or diabetes) does not matter
  • Your health outcomes can be followed up for at least 30 days and up to 1 year after the procedure

Who may not be able to join:

  • Your blood vessel procedure is needed because of a physical injury (such as trauma), rather than poor blood flow
  • You need an amputation for a reason other than poor blood flow — for example, due to cancer, nerve damage, or injury without any associated poor blood flow
  • At the time you leave the hospital, you have another blood vessel procedure planned that is not related to your legs — for example, a procedure on the heart or neck arteries
  • At the time you leave the hospital, you are already planned to have an amputation or a repeat operation on the same leg due to poor blood flow
  • At the time you leave the hospital, you are already planned to have another major surgery that carries a high risk to your heart or blood vessels

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Edyta Sutkowska, Ph.D, Wroclaw Medical University

Phone: 48503077016

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Wroclaw Medical University
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

MACE (Major Adverse Cardiovascular Events) and MALE (Major Adverse Limb Events)-Number of Participants Experiencing MACEor MALE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov